title: Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. Wages.
authors.affiliation: INSERM, U1138, Equipe 22Centre de Recherche des Cordeliers, Université Paris 5Université Paris 6, Paris, France; IRIS (Institut de Recherches Internationales Servier), Suresnes, France.
authors.forename: Marie-Karelle
authors.initials: MK
authors.lastname: Riviere
authors.forename: Frédéric
authors.initials: F
authors.lastname: Dubois
authors.forename: Sarah
authors.initials: S
authors.lastname: Zohar
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D020714:Maximum Tolerated Dose
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations